Sieviläinen, M, Almahmoudi, R, Al‐Samadi, A, Salo, T, Pirinen, M, Almangush, A. The prognostic value of immune checkpoints in oral squamous cell carcinoma. Oral Dis. 2019; 25: 1435– 1445. https://doi.org/10.1111/odi.12991
The prognostic value of immune checkpoints in oral squamous cell carcinoma
|Author:||Sieviläinen, Meri1; Almahmoudi, Rabeia1; Al-Samadi, Ahmed1;|
1Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki
2Medical Research Centre, Oulu University Hospital
3Department of Diagnostics and Oral Medicine, Medical Faculty, Research Group of Cancer Research and Translational Medicine, University of Oulu
4Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Science HiLIFE, University of Helsinki
5Department of Public Health, University of Helsinki
6Department of Mathematics and Statistics, University of Helsinki
7Department of Pathology, University of Helsinki
8Institute of Dentistry, University of Misurata
|Online Access:||PDF Full Text (PDF, 0.4 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2018120750108
John Wiley & Sons,
|Publish Date:|| 2019-10-13
Background: Despite the importance of immune checkpoints in immunotherapy, the prognostic value of these molecules remains controversial in oral squamous cell carcinoma (OSCC). We performed a systematic review to investigate the prognostic significance of the immune checkpoints in OSCC.
Materials: A systematic search was conducted in Ovid Medline, Scopus and Cochrane libraries, and all studies that evaluated the prognostic significance of immune checkpoints in OSCC were systematically retrieved.
Results: Twelve immune checkpoints/modulators were studied for their prognostic values in OSCC patients between 1985 and 2017. Seven immune checkpoints (FKBP51, B7‐H4, B7‐H6, ALHD1, PD‐L1, B7‐H3 and IDO1) were reported to be associated with poor patients’ survival in at least one study, and five (CTLA‐4, TLT‐2, VISTA, PD‐L2 and PD‐1) did not have a significant prognostic value. PD‐L1 results were controversial as it was reported to be associated with both better and worse patients’ survival.
Conclusions: Even though immune checkpoint markers had high expectation for OSCC prognostication, our systematic review revealed that the majority of them had been studied only once. The other molecules, which had been studied more than once, had controversial findings, except B7‐H3.
|Pages:||1435 - 1445|
|Type of Publication:||
A2 Review article in a scientific journal
|Field of Science:||
The authors acknowledge the funders of this study: the Sigrid Jusélius Foundation, the Cancer Society of Finland, the Oulu University Hospital MRC grant, the Emil Aaltonen Foundation, the Helsinki University Central Hospital research funds, the Academy of Finland, Eteläsuomalaisten ylioppilaiden säätiö, Helsingin seudun hammaslääkärit and the Finnish Dental Society (Apollonia).
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved. This is the peer reviewed version of the following article: Sieviläinen, M., Almahmoudi, R., Al-Samadi, A., Salo, T., Pirinen, M., Almangush, A. (2018) The prognostic value of immune checkpoints in oral squamous cell carcinoma. Oral Diseases. doi:10.1111/odi.12991, which has been published in final form at https://doi.org/10.1111/odi.12991. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.